Interleukin-17A Antagonist [EPC] class drugs

1 result
  • cosentyx - secukinumab injection

    (Secukinumab)
    Novartis Pharmaceuticals Corporation
    COSENTYX is indicated for treating moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis in children 4 years and older, and moderate to severe hidradenitis suppurativa in patients 12 years and older.